Pfizer secures up to $1.5 billion from Blackstone for obesity drug development
Summary
Pharmaceutical giant Pfizer has reached a funding agreement with Blackstone worth up to $1.5 billion. The capital will be specifically allocated to support the ongoing development of the company's experimental obesity medications.
Source: Read the full story at Stock Market News
Disclaimer: This content is for informational and educational purposes only and is not financial, investment or trading advice. Tech & Money Press is not a registered investment adviser or broker-dealer. Trading stocks, options and crypto involves substantial risk, including the loss of your entire investment. Do your own research and consult a licensed professional before making any financial decision. The authors may hold positions in the securities mentioned. News summaries are written with AI assistance from the original publisher's report and may contain errors; always check the original source. Full disclaimer.